Aquestive Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Aquestive Therapeutics
AQST Stock  USD 4.10  1.15  38.98%   
Analyzing historical trends in various income statement and balance sheet accounts from Aquestive Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aquestive Therapeutics' valuation are summarized below:
Gross Profit
26.2 M
Profit Margin
(1.59)
Market Capitalization
359.9 M
Enterprise Value Revenue
6.2728
Revenue
43.4 M
There are currently one hundred twenty fundamental signals for Aquestive Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Aquestive Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 291.8 M in 2026, whereas Enterprise Value is likely to drop slightly above 128.4 M in 2026.

Aquestive Therapeutics Total Revenue

49.61 Million

Check Aquestive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aquestive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.3 M, Selling General Administrative of 44.5 M or Total Revenue of 49.6 M, as well as many indicators such as Price To Sales Ratio of 3.99, Dividend Yield of 0.0 or Days Sales Outstanding of 63.82. Aquestive financial statements analysis is a perfect complement when working with Aquestive Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aquestive Stock
Check out the analysis of Aquestive Therapeutics Correlation against competitors.
For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Aquestive Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets62.8 M116.6 M57.5 M
Slightly volatile
Other Current Liabilities6.5 M7.6 M5.3 M
Slightly volatile
Total Current Liabilities20.1 M21.7 M17.4 M
Slightly volatile
Accounts Payable9.6 M11.8 M8.8 M
Slightly volatile
Cash86.4 M82.3 M31.5 M
Slightly volatile
Other Assets1.091.151.6 M
Pretty Stable
Long Term Debt41 M37.4 M37.9 M
Pretty Stable
Net Receivables7.7 M8.4 M8.6 M
Very volatile
Inventory4.1 M7 M3.9 M
Slightly volatile
Total Liabilities105.4 M185.8 M95.8 M
Slightly volatile
Short and Long Term Debt22.2 K23.4 K18.1 M
Slightly volatile
Total Current Assets106.5 M101.5 M46 M
Slightly volatile
Short Term Debt458.3 K482.4 K15.7 M
Slightly volatile
Intangible Assets587.7 K1.2 M601.3 K
Pretty Stable
Common Stock77.8 K81.9 K5.4 M
Slightly volatile
Property Plant Equipment7.7 M7.1 M10.8 M
Slightly volatile
Other Liabilities117.8 M112.2 M41.5 M
Slightly volatile
Cash And Short Term Investments86.4 M82.3 M32.3 M
Slightly volatile
Short and Long Term Debt Total47.8 M34.2 M77.7 M
Slightly volatile
Property Plant And Equipment Net8.6 M8.1 M12 M
Slightly volatile
Current Deferred Revenue1.1 M1.2 M964.3 K
Slightly volatile
Non Current Assets Total16.3 M15.2 M15.4 M
Pretty Stable
Non Currrent Assets Other1.3 M1.4 M1.9 M
Slightly volatile
Common Stock Shares Outstanding104.7 M99.7 M41.8 M
Slightly volatile
Long Term Debt Total53.8 M54.3 M67.5 M
Slightly volatile
Liabilities And Stockholders Equity71.9 M116.6 M59.6 M
Slightly volatile
Non Current Liabilities Total103.5 M164.1 M81.9 M
Slightly volatile
Capital Surpluse112.1 M200.8 M83.9 M
Slightly volatile
Other Current Assets2.5 M3.8 M1.6 M
Slightly volatile
Other Stockholder Equity365.8 M348.4 M133.1 M
Slightly volatile
Property Plant And Equipment Gross63.4 M60.4 M23.3 M
Slightly volatile
Preferred Stock Total Equity87.6 M93 M81 M
Slightly volatile
Deferred Long Term Liabilities840 K945 K1 M
Slightly volatile
Long Term Investments4.8 K5.4 K5.9 K
Slightly volatile
Net Working Capital83.7 M79.8 M29.3 M
Slightly volatile
Common Stock Total Equity37.1 K47.1 K31.9 K
Slightly volatile
Capital Stock55 K104.7 K41.7 K
Slightly volatile
Good Will228.8 K257.4 K281 K
Slightly volatile
Capital Lease Obligations4.8 M6.3 M4 M
Slightly volatile
Non Current Liabilities Other16.7 M20.3 M9.5 M
Slightly volatile

Aquestive Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative44.5 M57.7 M37.7 M
Slightly volatile
Total Revenue49.6 M66.2 M51.1 M
Slightly volatile
Gross Profit33 M45.6 M34.4 M
Slightly volatile
Research Development17.2 M23.3 M16.9 M
Slightly volatile
Cost Of Revenue16.6 M20.6 M16.7 M
Slightly volatile
Total Operating Expenses62.1 M81 M54.7 M
Slightly volatile
Interest Income4.2 M4 M4.7 M
Very volatile
Depreciation And Amortization613.9 K646.2 K2.9 M
Slightly volatile
Other Operating Expenses92.8 M101.6 M74.7 M
Slightly volatile
Reconciled Depreciation613.9 K646.2 K2.9 M
Slightly volatile

Aquestive Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation613.9 K646.2 K2.7 M
Slightly volatile
Capital Expenditures135.9 K143.1 K1.1 M
Slightly volatile
Total Cash From Financing Activities100.9 M96.1 M30.1 M
Slightly volatile
Change To Netincome11.8 M23.4 M12.1 M
Slightly volatile
End Period Cash Flow86.4 M82.3 M32.1 M
Slightly volatile
Begin Period Cash Flow31.7 M27.5 M22.8 M
Slightly volatile
Other Non Cash Items8.5 M12.1 M6.6 M
Slightly volatile
Stock Based Compensation7.4 M6.4 M18.7 M
Slightly volatile
Issuance Of Capital Stock79.2 M75.4 M56.1 M
Slightly volatile
Dividends Paid2.6 K2.7 K1.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.996.175.2015
Slightly volatile
Days Sales Outstanding63.8253.5564.5322
Slightly volatile
Stock Based Compensation To Revenue0.180.140.2939
Slightly volatile
Capex To Depreciation0.360.20.3605
Slightly volatile
EV To Sales4.245.55.4942
Slightly volatile
Inventory Turnover4.883.44.8406
Slightly volatile
Days Of Inventory On Hand71.3411180.6433
Slightly volatile
Payables Turnover2.062.02.102
Slightly volatile
Sales General And Administrative To Revenue0.50.960.7146
Slightly volatile
Research And Ddevelopement To Revenue0.390.410.3353
Slightly volatile
Capex To Revenue0.0030.00320.0184
Pretty Stable
Cash Per Share1.170.950.8203
Slightly volatile
Days Payables Outstanding227242189
Slightly volatile
Intangibles To Total Assets0.0210.020.0107
Slightly volatile
Current Ratio4.424.212.5707
Slightly volatile
Receivables Turnover7.929.016.4949
Slightly volatile
Capex Per Share0.0020.00210.0359
Slightly volatile
Revenue Per Share0.730.761.7721
Slightly volatile
Interest Debt Per Share0.690.731.6865
Slightly volatile
Debt To Assets0.840.430.8249
Slightly volatile
Operating Cycle118153143
Pretty Stable
Days Of Payables Outstanding227242189
Slightly volatile
Ebt Per Ebit1.571.6510.0469
Slightly volatile
Quick Ratio4.123.922.325
Slightly volatile
Net Income Per E B T1.121.151.0423
Slightly volatile
Cash Ratio3.583.411.5973
Slightly volatile
Days Of Inventory Outstanding71.3411180.6433
Slightly volatile
Days Of Sales Outstanding63.8253.5564.5322
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.830.91.0482
Slightly volatile
Fixed Asset Turnover4.185.774.5609
Slightly volatile
Debt Ratio0.840.430.8249
Slightly volatile
Price Sales Ratio3.996.175.2015
Slightly volatile
Asset Turnover1.00.651.0403
Slightly volatile
Gross Profit Margin0.730.790.6827
Very volatile

Aquestive Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap291.8 M277.9 M158.6 M
Slightly volatile
Enterprise Value128.4 M247.7 M143.4 M
Slightly volatile

Aquestive Fundamental Market Drivers

Aquestive Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aquestive Therapeutics Financial Statements

Aquestive Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aquestive Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aquestive Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aquestive Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M1.1 M
Total Revenue66.2 M49.6 M
Cost Of Revenue20.6 M16.6 M
Stock Based Compensation To Revenue 0.14  0.18 
Sales General And Administrative To Revenue 0.96  0.50 
Research And Ddevelopement To Revenue 0.41  0.39 
Revenue Per Share 0.76  0.73 
Ebit Per Revenue(0.61)(0.65)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY